PBYI — PUMA BIOTECHNOLOGY, INC.

—
Nasdaq · Health Care · Pharmaceuticals · CIK 1401667 ·
Last close
$7.14
Market Cap
$369.13M
52W High
$11.50
52W Low
$4.80
ADV30
441,890
Next earnings
2026-11-05
Puma Biotechnology, Inc., a biopharmaceutical company, focuses on the development and commercialization of products to enhance cancer care in the United States and internationally. It offers NERLYNX, an oral version of neratinib that is used to treat adult patients with early stage HER2-overexpressed/amplified breast cancer; and advanced or metastatic HER2-positive breast cancer when combined with capecitabine. The company also develops alisertib, a small molecule inhibitor of aurora kinase A for the treatment of hormone receptor positive breast cancer, triple negative breast cancer, small cell lung cancer, and head and neck cancer. It sells its products through specialty pharmacy and distributor networks. The company has license agreements with Pfizer Inc. for the development, manufacture, and commercialization of neratinib (oral), neratinib (intravenous), PB357, and related compounds, as well as sub-license agreements with Specialised Therapeutics Asia Pte Ltd., Medison Pharma Ltd., Pint Pharma International SA, Knight Therapeutics, Inc., Pierre Fabre Medicament SAS, and Bixink Therapeutics Co., Ltd. Puma Biotechnology, Inc. was founded in 2010 and is headquartered in Los Angeles, California.

Quarterly Fundamentals

Revenues vs Net Income (last 4 Q)

Assets vs Liabilities (last 4 Q)

PeriodRevenuesGross profitOp incomeNet incomeAssetsCashLiabilities
Sep 2026 — — — — — — —
Jun 2026 56,502,000 44,027,000 7,585,000 8,189,000 192,736,000 36,537,000 54,192,000
Mar 2026 44,814,000 34,390,000 -3,828,000 -3,753,000 192,699,000 36,193,000 64,283,000
Dec 2025 75,453,000 52,326,000 17,106,000 13,438,000 216,302,000 29,635,000 85,962,000

Cashflow TTM (yfinance, fills SEC gap)

Operating CF
$46,038,000
Investing CF
$-26,245,000
Financing CF
$-33,861,000
CapEx
$-107,000
Dividends Paid
—
Buybacks
—
EPS Diluted TTM
$0.46
As of
2026-11-15

Balance + Analyst (yfinance extras)

Retained Earnings
$-1,273,383,000
Inventory
$11,491,000
Receivables
$32,828,000
ST Investments
$67,027,000
EBIT TTM
$30,127,000
Pretax Income TTM
$28,097,000
Interest Exp TTM
$2,030,000
Analysts
—

Yahoo Snapshot (yfinance, live)

Total Revenue
$231,824,992
EBITDA
$35,547,000
Free Cash Flow
$37,679,876
Enterprise Value
$297,987,232
Total Cash
$108,575,000
Total Debt
$4,866,000
Shares Out
51,698,356
Trailing EPS
$0.46
Book Value
$2.84
ROE
18.2%
ROA
8.1%
Div Yield
0.00%

Annual Trend (SEC EDGAR, last 4y)

Revenues vs Net Income (last 4y)

FY endRevenuesOp incomeNet incomeAssetsLiabilitiesEquityOp cash flow
Dec 2025 228,371,000 37,299,000 31,111,000 216,302,000 85,962,000 130,340,000 41,802,000
Dec 2024 230,468,000 30,966,000 30,278,000 213,333,000 121,208,000 92,125,000 38,918,000
Dec 2023 235,637,000 32,640,000 21,591,000 230,528,000 177,086,000 53,442,000 27,009,000
Dec 2022 228,031,000 30,720,000 2,000 222,059,000 200,451,000 21,608,000 -15,827,000

TTM Snapshot

Revenues TTM
$231,244,000
NetIncome TTM
$26,718,000
OpCashFlow TTM
—
Assets (Latest)
$192,736,000
Forward EPS
$0.35

Max Pain — expiry 2026-12-18 (volume-derived — Yahoo OI feed degraded)

max pain strike: $7.50 · spot: $7.22 · call volume: 23 · put volume: 27
Expected Move to 2026-12-18: ±$1.65 (22.85%) — implied range $5.57 – $8.87 · ATM straddle on $7.50 strike

Peers — same industry

TickerNameMarket CapLastDaily %
NIKA NIKA PHARMACEUTICALS, INC $369.14M $0.35 —
SPRY ARS Pharmaceuticals, Inc. $366.93M $3.65 —
CRMD CorMedix Inc. $371.44M $4.67 —
CYDY CytoDyn Inc. $366.64M $0.25 —
PEPG PepGen Inc. $365.73M $3.88 —

News headlines (Yahoo Finance, 1h cache)

Puma Biotechnology Inc (PBYI) (Q3 2026) Earnings Call Highlights: Debt-Free and Raising ...
2026-11-06 23:11 · Yahoo
Puma Biotechnology (PBYI) Q3 2026 Earnings Call Transcript
2026-11-06 17:33 · Yahoo
Puma Biotechnology, Inc. Q3 2026 Earnings Call Summary
2026-11-06 13:30 · Yahoo
Puma Biotech: Q3 Earnings Snapshot
2026-11-05 22:17 · Yahoo
Puma Biotechnology Reports Third Quarter 2026 Financial Results
2026-11-05 21:05 · Yahoo
Puma Biotechnology to Host Conference Call to Discuss Third Quarter 2026 Financial Results
2026-10-22 20:11 · Yahoo
Will Nerlynx Continue to Aid Puma Biotechnology's Top Line in Q3?
2026-10-20 12:40 · Yahoo
The Zacks Analyst Blog Highlights AstraZeneca, Roche, Puma Biotechnology and Olema Oncology
2026-10-19 12:00 · Yahoo
PBYI's Alisertib Combo Phase II Study in Small Cell Lung Cancer Begins
2026-09-18 14:48 · Yahoo
Puma Biotechnology Initiates ALISCA®-Lung2, a Phase II Trial of Alisertib in Combination with Paclitaxel for the Treatment of Patients with Advanced Small Cell Lung Cancer
2026-09-17 20:07 · Yahoo

Recent Insider Activity

No insider activity indexed for this ticker.